$391 Million is the total value of 5AM Venture Management, LLC's 24 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| JANX | Exit | JANUX THERAPEUTICS INC | $0 | – | -446,266 | -100.0% | -1.58% | – |
| Exit | CINCOR PHARMA INC | $0 | – | -4,937,646 | -100.0% | -16.31% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| HOMOLOGY MEDICINES INC | 16 | Q3 2023 | 26.6% |
| ARVINAS INC | 16 | Q3 2023 | 14.3% |
| Crinetics Pharmaceuticals, Inc. | 16 | Q3 2023 | 12.8% |
| SCPHARMACEUTICALS INC | 16 | Q3 2023 | 7.5% |
| CIDARA THERAPEUTICS INC | 16 | Q3 2023 | 1.7% |
| IDEAYA BIOSCIENCES INC | 14 | Q1 2023 | 11.4% |
| VOR BIOPHARMA INC | 11 | Q3 2023 | 51.9% |
| CABALETTA BIO INC | 11 | Q2 2022 | 14.2% |
| AKOUOS INC | 10 | Q3 2022 | 27.7% |
| IMPEL PHARMACEUTICALS INC | 10 | Q3 2023 | 7.1% |
View 5AM Venture Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-03 |
| 13F-HR | 2021-11-15 |
View 5AM Venture Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.